Have a feature idea you'd love to see implemented?
Let us know!
ERNA Eterna Therapeutics Inc
Price (delayed)
$0.5322
Market cap
$27.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.31
Enterprise value
$61.55M
Highlights
The gross margin has soared by 166% from the previous quarter and by 131% YoY
The debt is down by 22% QoQ and by 2.8% YoY
Eterna Therapeutics's net income has plunged by 125% YoY and by 88% from the previous quarter
Eterna Therapeutics's EPS has plunged by 110% YoY and by 88% from the previous quarter
Key stats
What are the main financial stats of ERNA
Market
Valuations
Earnings
Shares outstanding
51.37M
Market cap
$27.34M
Enterprise value
$61.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
102.93
Revenue
$598,000
EBIT
-$41.04M
EBITDA
-$38.98M
Free cash flow
-$17.34M
Per share
Balance sheet
Liquidity
EPS
-$8.31
Free cash flow per share
-$3.2
Book value per share
-$8.39
Revenue per share
$0.11
TBVPS
$1.05
Total assets
$7.72M
Total liabilities
$53.11M
Debt
$38.47M
Equity
-$45.39M
Working capital
-$5.22M
Debt to equity
-0.85
Current ratio
0.48
Quick ratio
0.45
Net debt/EBITDA
-0.88
Margins
Efficiency
Dividend
EBITDA margin
-6,519.1%
Gross margin
72.9%
Net margin
-7,513.9%
Operating margin
-3,453.5%
Return on assets
-117.5%
Return on equity
N/A
Return on invested capital
-64.1%
Return on capital employed
N/A
Return on sales
-6,862%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ERNA stock price
How has the Eterna Therapeutics stock price performed over time
Intraday
-13.42%
1 week
-43.94%
1 month
-46.24%
1 year
-47.31%
YTD
-70.43%
QTD
-49.31%
Financial performance
How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$598,000
Gross profit
$436,000
Operating income
-$20.65M
Net income
-$44.93M
Gross margin
72.9%
Net margin
-7,513.9%
The gross margin has soared by 166% from the previous quarter and by 131% YoY
Eterna Therapeutics's net income has plunged by 125% YoY and by 88% from the previous quarter
ERNA's operating margin has surged by 92% year-on-year and by 75% since the previous quarter
The net margin has soared by 81% YoY and by 49% QoQ
Growth
What is Eterna Therapeutics's growth rate over time
Valuation
What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
102.93
Eterna Therapeutics's EPS has plunged by 110% YoY and by 88% from the previous quarter
The P/S is 94% lower than the last 4 quarters average of 80.9
Efficiency
How efficient is Eterna Therapeutics business performance
The ROA has plunged by 142% from the previous quarter and by 101% YoY
The company's return on invested capital has shrunk by 121% QoQ and by 10% YoY
Eterna Therapeutics's ROS has soared by 82% YoY and by 49% from the previous quarter
Dividends
What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ERNA.
Financial health
How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 85% lower than its total liabilities
Eterna Therapeutics's total assets has shrunk by 85% YoY and by 83% QoQ
The quick ratio has plunged by 58% YoY and by 38% from the previous quarter
The debt is 185% higher than the equity
The debt to equity has plunged by 108% YoY but it has soared by 85% from the previous quarter
The debt is down by 22% QoQ and by 2.8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.